John R. Burnett

Wellington Street
Perth, WA 6847, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 118 publications

Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management.

Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management.

Journal: Expert opinion on emerging drugs
Published: April 19, 2026

ANGPTL3 gene editing with CRISPR-Cas9: early trial insights.

ANGPTL3 gene editing with CRISPR-Cas9: early trial insights.

Journal: Expert opinion on investigational drugs
Published: April 03, 2026

Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a).

Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a).

Journal: Expert opinion on investigational drugs
Published: November 29, 2025

Assessing the clinical progress of muvalaplin for reducing lipoprotein(a).

Assessing the clinical progress of muvalaplin for reducing lipoprotein(a).

Journal: Expert opinion on investigational drugs
Published: November 10, 2025

Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials.

Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials.

Journal: Expert opinion on investigational drugs
Published: October 03, 2025

Lomitapide for the treatment of pediatric homozygous familial hypercholesterolemia.

Lomitapide for the treatment of pediatric homozygous familial hypercholesterolemia.

Journal: Expert opinion on pharmacotherapy
Published: August 08, 2025

An evaluation of recaticimab for the treatment of hypercholesterolemia.

An evaluation of recaticimab for the treatment of hypercholesterolemia.

Journal: Expert opinion on biological therapy
Published: May 17, 2025

Sepiapterin for the treatment of phenylketonuria.

Sepiapterin for the treatment of phenylketonuria.

Journal: Expert opinion on pharmacotherapy
Published: April 24, 2025

Incidental Finding of Severe Hypertriglyceridaemia and Diagnosis of Familial Chylomicronaemia Syndrome in a Family.

Incidental Finding of Severe Hypertriglyceridaemia and Diagnosis of Familial Chylomicronaemia Syndrome in a Family.

Journal: Journal of paediatrics and child health
Published: January 20, 2025

Response to the letter to the editor: 'Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia'.

Response to the letter to the editor: 'Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia'.

Journal: Expert opinion on pharmacotherapy
Published: November 30, 2024

Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia.

Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia.

Journal: Expert opinion on investigational drugs
Published: October 05, 2024

Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia.

Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia.

Journal: Expert opinion on pharmacotherapy
Published: September 21, 2024
Showing 1-12 of 118

Last Updated: 09/26/2026